ArtVentive Medical Group, Inc.: 10-K filed 2012-03-28

Name: ArtVentive Medical Group, Inc.: 10-K filed 2012-03-28
Creator: ArtVentive Medical Group, Inc.
License: https://creativecommons.org/licenses/by/4.0/

What ArtVentive Medical Group, Inc. reported in its annual report filed 2012-03-28 (fiscal FY 2011): 17 published measures, 42 facts as tagged in accession 0001056520-12-000101.

This filing

Form: 10-K (annual report)
Filed: 2012-03-28
Fiscal period: fiscal FY 2011
Accession: 0001056520-12-000101 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ArtVentive Medical Group, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-12-31	101,193	USD
At 2010-12-31	186,077	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2011-12-31	-273,257	USD
At 2010-12-31	143,611	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-2,607,617	USD	365
2007-01-23 to 2011-12-31	-3,887,909	USD	1804
2010-01-01 to 2010-12-31	-1,075,769	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-2,253,204	USD	365
2007-01-23 to 2011-12-31	-3,335,979	USD	1804
2010-01-01 to 2010-12-31	-982,984	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	2,175,000	USD	365
2007-01-23 to 2011-12-31	3,436,080	USD	1804
2010-01-01 to 2010-12-31	1,100,000	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2007-01-23 to 2011-12-31	-1,880	USD	1804
2010-01-01 to 2010-12-31	-1,382	USD	365

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	48,083,187	shares	365
2010-01-01 to 2010-12-31	45,799,740	shares	365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2011-12-31	876	USD
At 2010-12-31	1,152	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-2,607,617	USD	365
2007-01-23 to 2011-12-31	-3,887,909	USD	1804
2010-01-01 to 2010-12-31	-1,075,769	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-12-31	99,269	USD
At 2010-12-31	184,925	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-12-31	374,450	USD
At 2010-12-31	42,466	USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	572,640	USD	365
2007-01-23 to 2011-12-31	1,105,993	USD	1804
2010-01-01 to 2010-12-31	374,879	USD	365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	2,035,098	USD	365
2007-01-23 to 2011-12-31	2,739,392	USD	1804
2010-01-01 to 2010-12-31	704,294	USD	365

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2011-12-31	3,565,403	USD
At 2010-12-31	1,377,089	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2011-12-31	-506	USD
At 2010-12-31	-230	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	-2,607,617	USD	365
2007-01-23 to 2011-12-31	-3,887,909	USD	1804
2010-01-01 to 2010-12-31	-1,075,769	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2011-01-01 to 2011-12-31	331,963	USD	365
2007-01-23 to 2011-12-31	374,429	USD	1804
2010-01-01 to 2010-12-31	38,055	USD	365

Inspect the source

Entity: ArtVentive Medical Group, Inc. / CIK 0001405249
Captured: 2026-09-23 02:53 UTC
SEC response SHA-256: 01b8937f2876d513617b1d921d4a98ec6f536680d197470785bad286f4947f07

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001405249.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))